MA28105A1 - Utilisation d'un derive du pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement des dyslipidemies et des maladies associees aux dyslipidemies et/ou a l'obesite - Google Patents
Utilisation d'un derive du pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement des dyslipidemies et des maladies associees aux dyslipidemies et/ou a l'obesiteInfo
- Publication number
- MA28105A1 MA28105A1 MA28959A MA28959A MA28105A1 MA 28105 A1 MA28105 A1 MA 28105A1 MA 28959 A MA28959 A MA 28959A MA 28959 A MA28959 A MA 28959A MA 28105 A1 MA28105 A1 MA 28105A1
- Authority
- MA
- Morocco
- Prior art keywords
- dyslipidemia
- obesity
- prevention
- preparation
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Utilisation d'un composé antagoniste des récepteurs CB1 aux cannabinoïdes, dérivé du pyrazole, choisi parmi le rimonabant et le N-pipéridino-5-(4-bromophényl) -1-(2,4-dichlorophényl) -4-ethylpyrazole-3-carboxamide, seul ou associé à un autre principe actif, pour la préparation de médicaments utiles dans la prévention et le traitement des dyslipidémies et des maladies associées aux dyslipidémies et/ou à l'obésité telles que le syndrome métabolique, les risques cardiovasculaires et les maladies hépatiques.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0312553A FR2861300B1 (fr) | 2003-10-24 | 2003-10-24 | Utilisation d'un derive du pyrazole, pour la preparation de medicaments utiles dans la prevention et le traitement du syndrome metabolique |
FR0314763A FR2861301B1 (fr) | 2003-10-24 | 2003-12-15 | Utilisation du derive du pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du syndrome metabolique. |
FR0401193A FR2861302A1 (fr) | 2003-10-24 | 2004-02-05 | Utilisation d'un derive du pyrazole, pour la preparation de medicaments utiles dans la prevention et le traitement du syndrome metabolique. |
FR0403252A FR2861303A1 (fr) | 2003-10-24 | 2004-03-26 | Utilisation d'un derive de pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du syndrome metabolique |
Publications (1)
Publication Number | Publication Date |
---|---|
MA28105A1 true MA28105A1 (fr) | 2006-08-01 |
Family
ID=34426973
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA28959A MA28105A1 (fr) | 2003-10-24 | 2006-04-24 | Utilisation d'un derive du pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement des dyslipidemies et des maladies associees aux dyslipidemies et/ou a l'obesite |
Country Status (18)
Country | Link |
---|---|
US (2) | US20070072907A1 (fr) |
EP (1) | EP1680117A2 (fr) |
JP (1) | JP2007509113A (fr) |
KR (1) | KR20060100443A (fr) |
AR (3) | AR047764A1 (fr) |
AU (1) | AU2004289078A1 (fr) |
BR (1) | BRPI0415538A (fr) |
CA (1) | CA2543582A1 (fr) |
FR (1) | FR2861303A1 (fr) |
IL (1) | IL175103A0 (fr) |
MA (1) | MA28105A1 (fr) |
ME (1) | MEP10608A (fr) |
NZ (1) | NZ547375A (fr) |
RS (1) | RS20060344A (fr) |
RU (1) | RU2357731C2 (fr) |
SG (1) | SG149078A1 (fr) |
TW (1) | TWI286935B (fr) |
WO (1) | WO2005046689A2 (fr) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1574211A1 (fr) | 2004-03-09 | 2005-09-14 | Inserm | Utilisation d'antagonistes des récepteurs CB1 pour la fabrication d'un médicament destiné au traitement des maladies hépatiques |
WO2007009700A2 (fr) * | 2005-07-15 | 2007-01-25 | Laboratorios Del Dr. Esteve, S.A. | Utilisation de composes pyrazoliniques substitues pour le traitement de parametres des lipides du syndrome metabolique |
EP1745782A1 (fr) * | 2005-07-15 | 2007-01-24 | Laboratorios Del Dr. Esteve, S.A. | Utilisation de pyrazolines substituées pour la fabrication d' un médicament pour le traitement de la syndrome métabolique |
EP1745781A1 (fr) * | 2005-07-15 | 2007-01-24 | Laboratorios Del Dr. Esteve, S.A. | Combinaison d'antagoniste du récepteur cannabinoide du type pyrazoline et de statin |
WO2007009694A1 (fr) * | 2005-07-15 | 2007-01-25 | Laboratorios Del Dr.Esteve, S.A. | Utilisation de composes pyrazoliniques substitues pour l'elaboration de medicaments destines au traitement du syndrome metabolique |
ES2330993B1 (es) * | 2005-07-15 | 2010-07-06 | Laboratorios Del Dr. Esteve, S.A. | Combinacion de antagonista del receptor de cannabinoides de tipo pirazolina y estatina. |
EP1946779A1 (fr) * | 2007-01-16 | 2008-07-23 | Laboratorios del Dr. Esteve S.A. | Combination de pyrazoline substitués et de médicaments contre la dyslipidémie |
EP1985295A1 (fr) | 2007-04-04 | 2008-10-29 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Inhibiteurs sélectifs de l'expression du récepteur CB2 et/ou activité pour le traitement de l'obésité et troubles liés à l'obésité |
KR101057485B1 (ko) | 2008-08-04 | 2011-08-17 | 서울대학교산학협력단 | 1,2-디티올티온 유도체를 함유하는 엘엑스알-알파 과다발현으로 인한 질병의 예방 및 치료용 약학 조성물 |
WO2010079241A1 (fr) | 2009-01-12 | 2010-07-15 | Fundacion Hospital Nacional De Paraplejicos Para La Investigacion Y La Integracion | Utilisation d'antagonistes et/ou d'agonistes inverses des récepteurs cb1 pour la préparation de médicaments qui augmentent l'excitabilité des motoneurones |
ES2349838B1 (es) * | 2009-05-04 | 2011-11-15 | Instituto Mediterraneo Para El Avance De La Biotecnologia Y La Investigacion Sanitaria (Fundacion Im | Derivados de pirazol bivalentes como inhibidores de ingesta |
RU2568896C2 (ru) * | 2013-07-31 | 2015-11-20 | Общество С Ограниченной Ответственностью "Научно-Производственная Фирма "Материа Медика Холдинг" | Лекарственное средство на основе вещества, влияющего на эндоканнабиноидную систему |
CA3077624A1 (fr) * | 2016-10-01 | 2018-04-05 | James Smeeding | Compositions pharmaceutiques comprenant une statine et un cannabinoide et leurs utilisations |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2758723B1 (fr) * | 1997-01-28 | 1999-04-23 | Sanofi Sa | Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments |
FR2789079B3 (fr) * | 1999-02-01 | 2001-03-02 | Sanofi Synthelabo | Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant |
FR2799124B1 (fr) * | 1999-10-01 | 2004-08-13 | Sanofi Synthelabo | Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments |
FR2814678B1 (fr) * | 2000-10-04 | 2002-12-20 | Aventis Pharma Sa | Association d'un antagoniste du recepteur cb1 et de sibutramine, les compositions pharmaceutiques les contenant et leur utilisation pour la traitement de l'obesite |
US20020091114A1 (en) * | 2000-10-04 | 2002-07-11 | Odile Piot-Grosjean | Combination of a CB1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity |
MXPA04002583A (es) * | 2001-09-21 | 2004-06-18 | Solvay Pharm Bv | Derivados de 4,5-dihidro-1h-pirazol novedosos que tienen actividad antagonistica del canabinoide (cb1). |
US6864268B2 (en) * | 2002-02-27 | 2005-03-08 | Pfizer Inc. | β3 adrenergic receptor agonists |
NZ534757A (en) * | 2002-03-12 | 2006-07-28 | Merck & Co Inc | Substituted amides |
CA2480856A1 (fr) * | 2002-04-05 | 2003-10-23 | Merck & Co., Inc. | Arylamides substituee |
GEP20084475B (en) * | 2002-07-09 | 2008-09-10 | Bristol Myers Squibb Co | Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method for their production |
JP2005533849A (ja) * | 2002-07-18 | 2005-11-10 | メルク エンド カムパニー インコーポレーテッド | 肥満治療のための組み合わせ療法 |
ATE375349T1 (de) * | 2002-08-02 | 2007-10-15 | Merck & Co Inc | Substituierte furo(2,3-b)pyridin derivate |
AU2003296895A1 (en) * | 2002-08-20 | 2004-05-04 | The Regents Of The University Of California | Combination therapy for controlling appetites |
US6869966B2 (en) * | 2002-09-30 | 2005-03-22 | Banyu Pharmaceutical Co., Ltd. | N-substituted-2-oxodihydropyridine derivatives |
US20040214804A1 (en) * | 2003-04-25 | 2004-10-28 | Pharmacia Corporation | Combination of an aldosterone receptor antagonist and an anti-obesity agent |
US20060160834A1 (en) * | 2003-06-06 | 2006-07-20 | Fong Tung M | Combination therapy for the treatment of hypertension |
WO2004110375A2 (fr) * | 2003-06-06 | 2004-12-23 | Merck & Co., Inc. | Polytherapie permettant de traiter le diabete |
US20060148721A1 (en) * | 2003-06-06 | 2006-07-06 | Erondu Ngozi E | Combination therapy for the treatment of dyslipidemia |
EP1663215A1 (fr) * | 2003-09-02 | 2006-06-07 | Solvay Pharmaceuticals GmbH | Nouvelle utilisation medicale d'antagonistes selectifs du receptor cb1 |
US7371759B2 (en) * | 2003-09-25 | 2008-05-13 | Bristol-Myers Squibb Company | HMG-CoA reductase inhibitors and method |
RU2006117637A (ru) * | 2003-10-24 | 2007-12-10 | Зольвай Фармасьютиклз Гмбх (De) | Комбинированное лечение ожирения с применением избирательных антагонистов cb1-рецептора и ингибиторов липаз |
EP1574211A1 (fr) * | 2004-03-09 | 2005-09-14 | Inserm | Utilisation d'antagonistes des récepteurs CB1 pour la fabrication d'un médicament destiné au traitement des maladies hépatiques |
JP2007533661A (ja) * | 2004-03-31 | 2007-11-22 | ニューロジェン・コーポレーション | 体重管理のための併用療法 |
US20050281868A1 (en) * | 2004-06-21 | 2005-12-22 | Fairfield Clinical Trials, Llc | Transdermal delivery system for statin combination therapy |
-
2004
- 2004-03-26 FR FR0403252A patent/FR2861303A1/fr not_active Withdrawn
- 2004-10-21 AR ARP040103811A patent/AR047764A1/es not_active Application Discontinuation
- 2004-10-22 BR BRPI0415538-6A patent/BRPI0415538A/pt not_active IP Right Cessation
- 2004-10-22 NZ NZ547375A patent/NZ547375A/en unknown
- 2004-10-22 KR KR1020067009975A patent/KR20060100443A/ko not_active Application Discontinuation
- 2004-10-22 EP EP04805278A patent/EP1680117A2/fr not_active Withdrawn
- 2004-10-22 TW TW093132275A patent/TWI286935B/zh not_active IP Right Cessation
- 2004-10-22 JP JP2006536128A patent/JP2007509113A/ja not_active Withdrawn
- 2004-10-22 RU RU2006117790/15A patent/RU2357731C2/ru not_active IP Right Cessation
- 2004-10-22 ME MEP-106/08A patent/MEP10608A/xx unknown
- 2004-10-22 WO PCT/FR2004/002715 patent/WO2005046689A2/fr active Application Filing
- 2004-10-22 SG SG200809686-9A patent/SG149078A1/en unknown
- 2004-10-22 CA CA002543582A patent/CA2543582A1/fr not_active Abandoned
- 2004-10-22 AU AU2004289078A patent/AU2004289078A1/en not_active Abandoned
- 2004-10-22 RS YUP-2006/0344A patent/RS20060344A/sr unknown
-
2006
- 2006-04-23 IL IL175103A patent/IL175103A0/en unknown
- 2006-04-24 US US11/410,226 patent/US20070072907A1/en not_active Abandoned
- 2006-04-24 MA MA28959A patent/MA28105A1/fr unknown
-
2007
- 2007-11-05 AR ARP070104905A patent/AR063551A2/es unknown
- 2007-11-05 AR ARP070104904A patent/AR063550A2/es unknown
-
2009
- 2009-05-11 US US12/463,652 patent/US20090215755A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
KR20060100443A (ko) | 2006-09-20 |
AR063551A2 (es) | 2009-01-28 |
AU2004289078A1 (en) | 2005-05-26 |
RU2357731C2 (ru) | 2009-06-10 |
AR047764A1 (es) | 2006-02-22 |
IL175103A0 (en) | 2008-04-13 |
AR063550A2 (es) | 2009-01-28 |
EP1680117A2 (fr) | 2006-07-19 |
SG149078A1 (en) | 2009-01-29 |
CA2543582A1 (fr) | 2005-05-26 |
WO2005046689A3 (fr) | 2005-10-13 |
BRPI0415538A (pt) | 2006-12-26 |
US20090215755A1 (en) | 2009-08-27 |
TW200526216A (en) | 2005-08-16 |
MEP10608A (en) | 2010-06-10 |
US20070072907A1 (en) | 2007-03-29 |
TWI286935B (en) | 2007-09-21 |
WO2005046689A2 (fr) | 2005-05-26 |
JP2007509113A (ja) | 2007-04-12 |
RS20060344A (en) | 2008-08-07 |
NZ547375A (en) | 2009-10-30 |
RU2006117790A (ru) | 2007-12-10 |
FR2861303A1 (fr) | 2005-04-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA28105A1 (fr) | Utilisation d'un derive du pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement des dyslipidemies et des maladies associees aux dyslipidemies et/ou a l'obesite | |
NO20064603L (no) | Anvendelse av antagonister av CBI-reseptoren av preparat anvendelig for behandling av leversykdommer. | |
RU2223116C2 (ru) | Применение производных арил (или гетероарил) азолилкарбинолов в приготовлении лекарственного средства для лечения нарушений, опосредованных избытком вещества p | |
WO2006047516A3 (fr) | Composes et compositions servant d'inhibiteurs d'activite de recepteur cannabinoide de type 1 | |
HK1051140A1 (en) | Use of central cannabinoid receptor antagonist forpreparing medicines designed to facilitate smokingcessation. | |
NO20084489L (no) | Azolopyrimidiner som inhibitorer av cannabinoid 1 aktivitet | |
MA31568B1 (fr) | Composes d'imidazothiazole modulant les sirtuines | |
WO2005121097A3 (fr) | Derives de pyrazole, compositions contenant lesdits composes et methodes d'utilisation | |
NO20033165D0 (no) | (+)-1-(3,4-diklorfenyl)-3-azabicyklo[3.1.0]heksan, sammensetning og anvendelse derav | |
NO20051870L (no) | 1H-1,2,4-triazol-3-karboksamidderivater som cannabinoid-CB1-reseptorligander | |
NO20072443L (no) | Fungicide aktive ingredienskombinasjoner | |
BG105749A (en) | Pyrazolecarboxylic acid derivatives, their preparation and pharmaceutical compositions containing them | |
IL176547A0 (en) | 1,3,5-trisubstituted 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity | |
TW200500361A (en) | Compositions, combinations, and methods for treating cardiovascular conditions and other associated conditions | |
MX2009007666A (es) | Mezclas de pesticidas. | |
LU92238I2 (fr) | 1-(4-Chlorophenyl)-4-(4-morpholinyl)-2,5-dihydro-1H-imidazol-2-one ou l'un de sls physiologiquement acceptables. autre formulation du composé chimiqu e:1-(4-Chlorophenyl)4-morpholino-imidazolin-2-one | |
AU2003299362A1 (en) | Derivative of 5-(4-bromophenyl)-1-(2,4-dichlorophenly)-4-ethyl-n-(piperidine-1-yl)-1h-pyrazol-3-carboxamide, the preparation and therapeutic use thereof | |
WO2007006790A3 (fr) | Combinaison de composes organiques | |
WO2008064310A3 (fr) | Mélanges de composés actifs sur les récepteurs opioïdes | |
TNSN06313A1 (fr) | Derive de pyrazole cristallin | |
MA29263B1 (fr) | Utilisation d'un derive du pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement des maladies renales | |
AR049475A1 (es) | Utilizacion de un derivado de pirazol para la preparacion de medicamentos utiles en la prevencion y el tratamiento de la bronquitis cronica, y de la bronconeumopatia cronica obstructiva | |
NO20062369L (no) | Anvendelse av et pyrazoldedvat for fiemstilling av medikamenter for a hindre og behandle dyslipideml og sykdommer assosiert med dyslipidemi og/eller fedme | |
FR2882265A1 (fr) | Utilisation d'un derive du pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du diabete du type 2. | |
TNSN08010A1 (fr) | Utilisation de la 4-(3, 4-dichloro-phenyl) -1, 2, 3, 4- tetrahydronaphtalen -1- ylamine pour le traitement du cancer |